Peter Smith, Remix Therapeutics CEO

Fol­low­ing po­ten­tial bil­lion-dol­lar J&J deal, RNA pro­cess­ing biotech Remix re­turns with fresh fi­nanc­ing

A few months ago, Remix Ther­a­peu­tics penned a deal with John­son & John­son that could end up be­ing worth more than $1 bil­lion dol­lars down the line.

Now, Remix is back with $70 mil­lion in new fi­nanc­ing as it con­tin­ues to de­vel­op its RNA pro­cess­ing tech­nol­o­gy, the com­pa­ny an­nounced this morn­ing. The Cam­bridge, MA-based biotech hous­es a dis­cov­ery plat­form aimed at drug­ging RNA pro­cess­ing, the un­sung (dif­fi­cult) mid­dle child in a phar­ma world that has large­ly paid more heed to pro­tein tar­gets and DNA ther­a­pies un­til re­cent­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.